| pubmed-article:9049825 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9049825 | lifeskim:mentions | umls-concept:C0028948 | lld:lifeskim |
| pubmed-article:9049825 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:9049825 | lifeskim:mentions | umls-concept:C0162768 | lld:lifeskim |
| pubmed-article:9049825 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:9049825 | lifeskim:mentions | umls-concept:C0908880 | lld:lifeskim |
| pubmed-article:9049825 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:9049825 | pubmed:dateCreated | 1997-5-15 | lld:pubmed |
| pubmed-article:9049825 | pubmed:abstractText | Ewing's sarcoma family of tumors (EFT) contain reciprocal translocations, of which approximately 90% occur between the long arm of chromosomes 11 and 22,t(11;22)(q24;q12) resulting in the formation of chimeric proteins generated by a fusion of the EWS and FLI-1 genes. To determine if EWS-FLI-1 protein is responsible for the Ewing sarcoma phenotype we have used sequence-specific antisense oligodeoxynucleotides (ODN) to block its expression. We have evaluated a series of antisense ODN directed toward the breakpoint region in an effort to prevent translation of the fusion messenger RNA. ODN were first evaluated in a cell-free in vitro translation system. Exogenously added RNase H was found to be required for translation inhibition. ODN that showed complete inhibition of translation were electroporated into TC-32 cells, a EFT cell line. Fusion protein and EWS protein levels were evaluated by Western blot analysis. A 40-60% decrease in the fusion protein was observed in TC-32 cells with antisense ODN directed toward the breakpoint region. Cell viability was reduced with antisense sequences in TC-32 cells but not in a prostate cancer cell line. Since inhibition of t(11:22) gene product is correlated to effects on cell viability reduction of the fusion protein may thus offer insight into the biology of EFT. | lld:pubmed |
| pubmed-article:9049825 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9049825 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9049825 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9049825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9049825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9049825 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9049825 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9049825 | pubmed:issn | 0167-594X | lld:pubmed |
| pubmed-article:9049825 | pubmed:author | pubmed-author:NeckersLL | lld:pubmed |
| pubmed-article:9049825 | pubmed:author | pubmed-author:BhatN KNK | lld:pubmed |
| pubmed-article:9049825 | pubmed:author | pubmed-author:ToretskyJ AJA | lld:pubmed |
| pubmed-article:9049825 | pubmed:author | pubmed-author:ConnellYY | lld:pubmed |
| pubmed-article:9049825 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9049825 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:9049825 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9049825 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9049825 | pubmed:pagination | 9-16 | lld:pubmed |
| pubmed-article:9049825 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:meshHeading | pubmed-meshheading:9049825-... | lld:pubmed |
| pubmed-article:9049825 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9049825 | pubmed:articleTitle | Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. | lld:pubmed |
| pubmed-article:9049825 | pubmed:affiliation | Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:9049825 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9049825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9049825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9049825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9049825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9049825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9049825 | lld:pubmed |
